Brokers Issue Forecasts for Fractyl Health FY2029 Earnings

Fractyl Health, Inc. (NASDAQ:GUTS) – Analysts at HC Wainwright boosted their FY2029 earnings estimates for Fractyl Health in a research note issued on Wednesday, March 25th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings of $0.37 per share for the year, up from their previous forecast of $0.31. HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Fractyl Health’s current full-year earnings is ($1.61) per share. HC Wainwright also issued estimates for Fractyl Health’s FY2030 earnings at $0.94 EPS.

A number of other equities research analysts also recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Fractyl Health in a research report on Monday, December 29th. Canaccord Genuity Group reiterated a “buy” rating and issued a $8.00 price objective on shares of Fractyl Health in a report on Thursday. Finally, Morgan Stanley lowered Fractyl Health from an “overweight” rating to an “equal weight” rating and reduced their price objective for the company from $8.00 to $2.00 in a research report on Thursday, January 29th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $5.40.

Fractyl Health Stock Down 5.4%

Shares of NASDAQ:GUTS opened at $0.47 on Thursday. Fractyl Health has a 52-week low of $0.38 and a 52-week high of $3.03. The firm has a fifty day moving average of $0.73 and a 200 day moving average of $1.28. The firm has a market capitalization of $75.07 million, a PE ratio of -0.26 and a beta of 1.51. The company has a debt-to-equity ratio of 3.23, a quick ratio of 4.27 and a current ratio of 4.78.

Fractyl Health (NASDAQ:GUTS) last issued its quarterly earnings results on Tuesday, March 24th. The company reported $0.15 EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.34.

Hedge Funds Weigh In On Fractyl Health

A number of large investors have recently added to or reduced their stakes in the business. Bank of America Corp DE increased its holdings in shares of Fractyl Health by 23.5% in the third quarter. Bank of America Corp DE now owns 88,634 shares of the company’s stock worth $141,000 after buying an additional 16,856 shares during the period. Jane Street Group LLC purchased a new stake in Fractyl Health during the 2nd quarter valued at about $31,000. FNY Investment Advisers LLC purchased a new stake in Fractyl Health during the 3rd quarter valued at about $31,000. Jump Financial LLC bought a new position in Fractyl Health during the 4th quarter worth approximately $57,000. Finally, Scientech Research LLC bought a new position in Fractyl Health during the 3rd quarter worth approximately $49,000.

Fractyl Health News Roundup

Here are the key news stories impacting Fractyl Health this week:

• Positive Sentiment: Q4 2025 results and earnings-call takeaways showed better-than-expected results and operational color that investors liked — management highlighted the quarter and outlook that helped drive upside reaction. Earnings Call Highlights
• Positive Sentiment: Analysts moved more bullish: HC Wainwright raised FY2029–FY2030 EPS estimates and reiterated a Buy with an $8 price target; Canaccord also reaffirmed a Buy and $8 PT — both signals can attract momentum buying given the large implied upside vs. the current price. Analyst Notes (MarketBeat) Canaccord Note
• Positive Sentiment: Shares jumped sharply in after-hours trading (reported ~21% move) on the combination of the results, call and analyst commentary — a clear short-term bullish reaction. After-hours Coverage
• Neutral Sentiment: The full Q4 2025 earnings call transcript is available for investors who want the exact management comments; use it to judge sustainability of the upbeat guidance and timing of any commercial/clinical milestones. Call Transcript
• Neutral Sentiment: Macro and micro risks remain: the consensus for the current fiscal year is still a material loss (analyst consensus ~-1.61 EPS), the stock is low-priced with thin liquidity and is trading below its 50- and 200-day averages — factors that can amplify volatility but not necessarily change the fundamental reaction to positive news.
• Negative Sentiment: The company disclosed a new regulation/compliance risk tied to global anti‑corruption and sanctions laws — this raises potential legal/compliance costs and execution risk that could weigh on valuation if it leads to investigations, fines, or limits on international activity. Compliance Risk Notice

About Fractyl Health

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.